tldrdailynews.com logo

FDA approves Rinvoq as first JAK inhibitor for Crohn's Disease.

1 min read
Source: FDA.gov
FDA approves Rinvoq as first JAK inhibitor for Crohn's Disease.
Photo: FDA.gov
TL;DR

FDA has approved Rinvoq (upadacitinib) as the first oral treatment for adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers. Rinvoq is a Janus kinase (JAK) inhibitor and should not be used in combination with other JAK inhibitors, biological therapies for Crohn’s disease, or with strong immunosuppressants such as azathioprine and cyclosporine. The most common side effects of Rinvoq are upper respiratory tract infections, anemia, fever, acne, herpes zoster, and headache.

Topics:businesshealthcare#crohns-disease#fda#healthcare#jak-inhibitors#oral-treatment#rinvoq
Share this article
  1. FDA approves first oral treatment for moderately to severely active Cr  FDA.gov
  2. With FDA nod for Crohn's, AbbVie wins 7th indication for Rinvoq  FiercePharma
  3. AbbVie gains Crohn's disease indication for Rinvoq in US (NYSE:ABBV)  Seeking Alpha
  4. FDA Approves Upadacitinib (Rinvoq) for Crohn's Disease  Medscape
  5. First JAK Inhibitor Approved for Crohn's Disease  Medpage Today

Want the full story? Read the original reporting

Read on FDA.gov